Invasive Streptococcus pneumoniae infections in children and older adults in the north of Spain before and after the introduction of the heptavalent pneumococcal conjugate vaccine

被引:34
作者
Perez-Trallero, E. [1 ,2 ,3 ]
Marimon, J. M. [1 ,2 ]
Ercibengoa, M. [2 ]
Vicente, D. [1 ,2 ]
Perez-Yarza, E. G. [4 ]
机构
[1] Hosp Donostia, Microbiol Serv, San Sebastian 20014, Spain
[2] Resp CIBERES, Ctr Invest Biomed Red Enfermedades, San Sebastian, Spain
[3] Univ Basque Country, Fac Med, Dept Med Prevent & Salud Publ, San Sebastian, Spain
[4] Hosp Donostia, Dept Pediat, San Sebastian 20014, Spain
关键词
DISEASE; SEROTYPES; IMPACT; ERA; EPIDEMIOLOGY; MENINGITIS; BACTEREMIA; MORTALITY; RESISTANT; TRENDS;
D O I
10.1007/s10096-008-0693-1
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
In the last two decades, an increasing trend in the incidence of pneumococcal disease in Europe has been reported. We investigated the effect of the use of the heptavalent pneumococcal conjugate vaccine (PCV7) in an area of northern Spain, where all recorded cases of invasive pneumococcal diseases (IPD) were included (n = 450; 91 between 1996-2007 in children aged < 5 years and 359 between 1998-2007 in adults aged > 64 years). All isolates were serotyped. In children, the overall IPD incidence did not significantly decrease after the introduction, in late 2001, of PCV7. However, the incidence of PCV7 serotypes significantly decreased by 137.2% from 31.59 cases/100,000 population in 1996-2001 to 13.42 in 2002-2007 (95% confidence interval [CI] -27.2 to -342.4%), as did the overall rates of penicillin resistance (from 45.6 to 18.6%) and multiresistance (from 30.3 to 11%). In older adults, the overall IPD incidence showed a non-significant increase due to non-PCV7 serotypes, which seemed to continue a previous trend in our region.
引用
收藏
页码:731 / 738
页数:8
相关论文
共 32 条
[1]  
[Anonymous], 1997, MMWR Recomm Rep, V46, P1
[2]   Reduction in pediatric invasive pneumococcal disease in the Basque Country and Navarre, Spain, after introduction of the heptavalent pneumococcal conjugate vaccine [J].
Aristegui, J. ;
Bernaola, E. ;
Pocheville, I. ;
Garcia, C. ;
Arranz, L. ;
Duran, G. ;
Perez, L. ;
Bastida, M. ;
Canduela, C. ;
Aguirre, M. Herranz ;
Garrote, E. ;
Fletcher, M. A. ;
Perez, C. .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2007, 26 (05) :303-310
[3]   Effectiveness of the 7-valent pneumococcal conjugate vaccine: A population-based case-control study [J].
Barricarte, Aurelio ;
Castilla, Jesus ;
Gil-Setas, Alberto ;
Torroba, Luis ;
Navarro-Alonso, Jose Antonio ;
Irisarri, Fatima ;
Arriazu, Maite .
CLINICAL INFECTIOUS DISEASES, 2007, 44 (11) :1436-1441
[4]   Pneumococcal meningitis in the era of pneumococcal conjugate vaccine implementation [J].
Bingen, E. ;
Levy, C. ;
Varon, E. ;
de la Rocque, F. ;
Boucherat, M. ;
d'Athis, P. ;
Aujard, Y. ;
Cohen, R. .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2008, 27 (03) :191-199
[5]   Serotyping Streptococcus pneumoniae by multiplex PCR [J].
Brito, DA ;
Ramirez, M ;
de Lencastre, H .
JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (06) :2378-2384
[6]   Geographic distribution and clonal diversity of Streptococcus pneumoniae serotype 1 isolates [J].
Brueggemann, AB ;
Spratt, BG .
JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (11) :4966-4970
[7]   Invasive pneumococcal disease among children in a health district of Barcelona:: early impact of pneumococcal conjugate vaccine [J].
Calbo, E. ;
Diaz, A. ;
Canadell, E. ;
Fabrega, J. ;
Uriz, S. ;
Xercavins, M. ;
Morera, M. A. ;
Cuchi, E. ;
Rodriguez-Carballeira, M. ;
Garau, J. .
CLINICAL MICROBIOLOGY AND INFECTION, 2006, 12 (09) :867-872
[8]  
Centers for Disease Control and Prevention, 2006, MMWR-MORBID MORTAL W, V55, P511
[9]  
Clinical and Laboratory Standards Institute (CLSI), 2007, M100S17 CLSI
[10]   Invasive pneumococcal disease in Portugal prior to and after the introduction of pneumococcal heptavalent conjugate vaccine [J].
Dias, Ricardo ;
Canica, Manuela .
FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 2007, 51 (01) :35-42